Curis Lifesciences Limited is a pharmaceutical manufacturer engaged in producing a wide range of tablets, capsules, oral liquids, ointments, sterile ophthalmic ointments, and external preparations. The company operates under three verticals — Loan License Manufacturing, Contract Manufacturing, and Direct Exports, catering to both domestic and international markets across over 35 countries, including the UK, Kenya, Nigeria, and Vietnam.

The Company is led by Promoter, i.e. MR. DHARMESH DASHARATHBHAI PATEL, MR. SIDDHANT JAYANTIBHAI PAWASIA, MR. PIYUSH GORDHANBHAI ANTALA AND MR. JAIMIK MANSUKHLAL PATEL.

The Revenues from operations for the Period ended on July 31, 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 1,950.51 Lakhs, ₹  4,964.50 Lakhs, â‚¹ 3,586.95 Lakhs, and ₹ 3,641.69 Lakhs, The EBITDA for the Period ended on July 31, 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 423.56 Lakhs, ₹  953.73 Lakhs, â‚¹  838.76 Lakhs, and ₹ 327.59 Lakhs, The Profit after Tax for the Period ended on July 31, 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were â‚¹ 287.16 Lakhs, ₹  610.51 Lakhs, â‚¹  486.70  Lakhs, and ₹  187.53 Lakhs, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of â‚¹ 10.29 and post-issue EPS of ₹ 7.55 for FY25. The pre-issue P/E ratio is 12.44x, while the post-issue P/E ratio is 16.95x against the Industry P/E ratio is 23x. The company's ROE for FY25 is 55.25% and RoNW is 37.62%. The Annualised EPS is ₹ 10.66x and P/E is 12.01x. These metrics suggest that the IPO is fully priced.

The Grey Market Premium (GMP) of Curis Lifesciences showing listing gains of 0.00 %.Given the company's financial performance and the valuation of the IPO, we recommend Investors to Avoid to the Finbud Financial Services Limited IPO for Listing gain or Long Term Purposes.